Benralizumab Injection Reduces Risk
According to media reports, this treatment is being seen as the biggest breakthrough in respiratory diseases in the last 50 years.
A report published in The Lancet Respiratory Medicine indicates that a new injection will be given to asthma and COPD (Chronic Obstructive Pulmonary Disease) patients, showing promising results. This injection, named Benralizumab, works as a monoclonal antibody. It targets eosinophils, a type of white blood cell, which can help reduce inflammation in the lungs. Asthma and COPD patients are at risk of developing severe complications due to inflammation in their lungs.
30% More Effective Than Current Treatments
Doctors state that while this treatment has been used in low doses for severe asthma, recent clinical trials have found that if it is injected during an asthma attack, it could be more effective. Experts have discovered that it could be up to 30% more effective than current treatments.
For this trial, 158 participants who required emergency medical care for asthma or COPD attacks were involved. The injection helped reduce symptoms and health complications.
What Did the Study Find?
For this study, the participants were divided into three groups. One group was given the Benralizumab injection along with dummy pills, the second group received standard care (prednisolone 30 mg per day for five days), and the third group received standard care along with the Benralizumab injection. The study results showed that after 28 days, participants who received the Benralizumab injection showed significant improvement in symptoms like coughing, wheezing, and shortness of breath. After 90 days, the Benralizumab group had significantly improved compared to the other groups.
Could Asthma Risks Decrease?
According to Professor Mona Bafdel from King’s College London, this could be a game-changer for people with asthma and COPD. These two diseases cause millions of deaths worldwide, and despite this, there has been no significant change in the treatment of asthma and COPD for the last 50 years. This is the biggest breakthrough in five decades. We hope that this important study will change the way asthma and COPD are treated in the future, leading to improvements in the health of more than one billion people suffering from these diseases globally.